Published in Medical Letter on the CDC and FDA, April 12th, 2006
"We are pleased that the FDA, upon review of the clinical and non-clinical data package from the work of our partner Schering AG, has agreed with the design of our proposed pharmacokinetic study. The primary endpoint will require assessment of the average serum testosterone levels (Cavg) at steady state, measured in hypogonadal men receiving Nebido via intramuscular injection every 12 weeks," stated Glenn...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.